Axogen reports Q4 2024 revenue $49.4M (+15.1% YoY); FY 2024 revenue $187.3M (+17.8%)

Axogen, Inc.

2024-FY EPS reported -$0.23 revenue$187,338,000

Q4 2024 revenue expected $49.4M, up 15.1% YoY; full-year 2024 revenue $187.3M, up 17.8%.
Full-year gross margin expected above 75.5%; cash and investments $39.5M, up $2.5M from 2023.
Growth driven by commercial execution in Extremities, OMF-Head & Neck, and Resensation adoption.
Investor Day scheduled for March 4, 2025 to discuss strategic priorities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.